-
公开(公告)号：US08632996B2
公开(公告)日：2014-01-21
申请号：US13492465
申请日：2012-06-08
申请人： Kenya Shitara , Nobuo Hanai , Emi Shoji , Mikiko Sakurada , Akiko Furuya , Kazuyasu Nakamura , Rinpei Niwa , Kenji Shibata , Motoo Yamasaki
发明人： Kenya Shitara , Nobuo Hanai , Emi Shoji , Mikiko Sakurada , Akiko Furuya , Kazuyasu Nakamura , Rinpei Niwa , Kenji Shibata , Motoo Yamasaki
IPC分类号： C12P21/00
CPC分类号： G01N33/543 , A61K2039/505 , C07K16/2866 , C07K2317/24 , C07K2317/565 , C07K2317/732 , C07K2319/00 , G01N2333/78
摘要： A recombinant antibody or the antibody fragment thereof which specifically reacts with an extracellular domain of human CCR4; a DNA which encodes the recombinant antibody or the antibody fragment thereof; a method for producing the recombinant antibody or the antibody fragment thereof; a method for immunologically detecting CCR4, a method for immunologically detecting a cell which expressed CCR4 on the cell surface, a method for depleting a cell which expresses CCR4 on the cell surface, and a method for inhibiting production of Th2 cytokine, which comprise using the recombinant antibody according or antibody fragment thereof; a therapeutic or diagnostic agent for Th2-mediated immune diseases; and a therapeutic or diagnostic agent for a blood cancer.
摘要翻译： 与人CCR4的细胞外结构域特异性反应的重组抗体或其抗体片段; 编码重组抗体或其抗体片段的DNA; 制备重组抗体或其抗体片段的方法; 用于免疫学检测CCR4的方法，用于免疫检测在细胞表面上表达CCR4的细胞的方法，用于在细胞表面上表达CCR4的细胞消耗的方法，以及抑制Th2细胞因子产生的方法，其包括使用 重组抗体或其抗体片段; Th2介导的免疫疾病的治疗或诊断剂; 和用于血液癌的治疗或诊断剂。
-
公开(公告)号：US08197814B2
公开(公告)日：2012-06-12
申请号：US12684651
申请日：2010-01-08
申请人： Kenya Shitara , Nobuo Hanai , Emi Shoji , Mikiko Sakurada , Akiko Furuya , Kazuyasu Nakamura , Rinpei Niwa , Kenji Shibata , Motoo Yamasaki
发明人： Kenya Shitara , Nobuo Hanai , Emi Shoji , Mikiko Sakurada , Akiko Furuya , Kazuyasu Nakamura , Rinpei Niwa , Kenji Shibata , Motoo Yamasaki
IPC分类号： A61K39/395
CPC分类号： G01N33/543 , A61K2039/505 , C07K16/2866 , C07K2317/24 , C07K2317/565 , C07K2317/732 , C07K2319/00 , G01N2333/78
摘要： A recombinant antibody or the antibody fragment thereof which specifically reacts with an extracellular domain of human CCR4; a DNA which encodes the recombinant antibody or the antibody fragment thereof; a method for producing the recombinant antibody or the antibody fragment thereof; a method for immunologically detecting CCR4, a method for immunologically detecting a cell which expressed CCR4 on the cell surface, a method for depleting a cell which expresses CCR4 on the cell surface, and a method for inhibiting production of Th2 cytokine, which comprise using the recombinant antibody according or antibody fragment thereof; a therapeutic or diagnostic agent for Th2-mediated immune diseases; and a therapeutic or diagnostic agent for a blood cancer.
摘要翻译： 与人CCR4的细胞外结构域特异性反应的重组抗体或其抗体片段; 编码重组抗体或其抗体片段的DNA; 制备重组抗体或其抗体片段的方法; 用于免疫学检测CCR4的方法，用于免疫检测在细胞表面上表达CCR4的细胞的方法，用于在细胞表面上表达CCR4的细胞消耗的方法，以及抑制Th2细胞因子产生的方法，其包括使用 重组抗体或其抗体片段; Th2介导的免疫疾病的治疗或诊断剂; 和用于血液癌的治疗或诊断剂。
-
公开(公告)号：US20110009600A1
公开(公告)日：2011-01-13
申请号：US12829836
申请日：2010-07-02
申请人： Kenya SHITARA , Rinpei Niwa , Akito Natsume
发明人： Kenya SHITARA , Rinpei Niwa , Akito Natsume
IPC分类号： C07K16/46
CPC分类号： C07K16/462 , A61K2039/505 , C07K16/2887 , C07K2317/24 , C07K2317/522 , C07K2317/524 , C07K2317/526 , C07K2317/53 , C07K2317/72 , C07K2317/732 , C07K2317/734
摘要： The present invention relates to a recombinant antibody composition having higher complement-dependent cytotoxic activity than a human IgG1 antibody and a human IgG3 antibody, wherein a polypeptide comprising a CH2 domain in the Fc region of a human IgG1 antibody is replaced by a polypeptide comprising an amino acid sequence which corresponds to the same position of a human IgG3 antibody indicated by the EU index as in Kabat, et al.; a DNA encoding the antibody molecule or a heavy chain constant region of the antibody molecule contained in the recombinant antibody composition; a transformant obtainable by introducing the recombinant vector into a host cell; a process for producing the recombinant antibody composition using the transformant; and a medicament comprising the recombinant antibody composition as an active ingredient.
摘要翻译： 本发明涉及具有比人IgG1抗体和人IgG3抗体更高的补体依赖性细胞毒活性的重组抗体组合物，其中包含人IgG1抗体的Fc区中的CH2结构域的多肽被包含 氨基酸序列对应于如Kabat等人的欧盟指数所示的人IgG3抗体的相同位置; 编码重组抗体组合物中包含的抗体分子或抗体分子的重链恒定区的DNA; 通过将重组载体导入宿主细胞获得的转化体; 使用该转化体生产重组抗体组合物的方法; 以及包含重组抗体组合物作为活性成分的药物。
-
公开(公告)号：US20120020962A1
公开(公告)日：2012-01-26
申请号：US13225811
申请日：2011-09-06
申请人： Ryuzo UEDA , Kenya SHITARA , Shiro AKINAGA , Rinpei NIWA , Masamichi KOIKE
发明人： Ryuzo UEDA , Kenya SHITARA , Shiro AKINAGA , Rinpei NIWA , Masamichi KOIKE
CPC分类号： C07K16/2866 , A61K2039/505 , C07K2317/24 , Y02A50/41 , Y02A50/412
摘要： The present invention relates to the method for depleting in vivo regulatory T cell, the method for suppressing IL-10 producing activity of regulatory T cell, the method for treating diseases in which pathologic conditions are deteriorated by regulatory T cell and the method for enhancing tumor immunity which comprises administering to a patient a monoclonal antibody which specifically binds to human CC chemokine 4 (CCR4) or the antibody fragment thereof.
摘要翻译： 本发明涉及体内调节性T细胞的消耗方法，抑制调节性T细胞的IL-10产生活性的方法，通过调节性T细胞治疗病变状态的疾病的治疗方法及增强肿瘤的方法 其包括向患者施用特异性结合人CC趋化因子4（CCR4）或其抗体片段的单克隆抗体。
-
公开(公告)号：US07923538B2
公开(公告)日：2011-04-12
申请号：US11491501
申请日：2006-07-24
申请人： Kenya Shitara , Rinpei Niwa , Akito Natsume
发明人： Kenya Shitara , Rinpei Niwa , Akito Natsume
IPC分类号： C12P21/08
CPC分类号： C07K16/462 , A61K2039/505 , C07K16/2887 , C07K2317/24 , C07K2317/522 , C07K2317/524 , C07K2317/526 , C07K2317/53 , C07K2317/72 , C07K2317/732 , C07K2317/734
摘要： The present invention relates to a recombinant antibody composition having higher complement-dependent cytotoxic activity than a human IgG1 antibody and a human IgG3 antibody, wherein a polypeptide comprising a CH2 domain in the Fc region of a human IgG1 antibody is replaced by a polypeptide comprising an amino acid sequence which corresponds to the same position of a human IgG3 antibody indicated by the EU index as in Kabat, et al.; a DNA encoding the antibody molecule or a heavy chain constant region of the antibody molecule contained in the recombinant antibody composition; a transformant obtainable by introducing the recombinant vector into a host cell; a process for producing the recombinant antibody composition using the transformant; and a medicament comprising the recombinant antibody composition as an active ingredient.
摘要翻译： 本发明涉及具有比人IgG1抗体和人IgG3抗体更高的补体依赖性细胞毒活性的重组抗体组合物，其中包含人IgG1抗体的Fc区中的CH2结构域的多肽被包含 氨基酸序列对应于如Kabat等人的欧盟指数所示的人IgG3抗体的相同位置; 编码重组抗体组合物中包含的抗体分子或抗体分子的重链恒定区的DNA; 通过将重组载体导入宿主细胞获得的转化体; 使用该转化体生产重组抗体组合物的方法; 以及包含重组抗体组合物作为活性成分的药物。
-
公开(公告)号：US20100310573A1
公开(公告)日：2010-12-09
申请号：US12647698
申请日：2009-12-28
申请人： Tomoaki NAKAGAWA , Sayaka HORI , Rinpei NIWA , Tsuguo KUBOTA , Kazuhiro MASUDA , Kazuyasu NAKAMURA
发明人： Tomoaki NAKAGAWA , Sayaka HORI , Rinpei NIWA , Tsuguo KUBOTA , Kazuhiro MASUDA , Kazuyasu NAKAMURA
IPC分类号： A61K39/395 , C12N15/63 , C07K16/28 , C07H21/04 , C07K16/30 , A61P35/00 , A61P37/08 , A61P37/00 , C12N5/10 , C12P21/08 , G01N33/574 , G01N33/566
CPC分类号： C07K16/2812 , A61K2039/505 , C07K2317/56 , C07K2317/565 , C07K2317/72 , C07K2317/732 , C07K2317/734 , C07K2317/92 , C07K2319/30 , G01N2333/70514
摘要： An anti-CD4 antibody which binds to CD4, has a high affinity and has a high effector activity, such as an antibody-dependent cellular cytotoxicity (ADCC activity) or complement-dependent cellular cytotoxicity (CDC activity), is required for a disease relating to a CD4-expressing cell.The present invention can provide a monoclonal antibody or an antibody fragment thereof, which binds to a CD4 extracellular region with high affinity and also exhibits a high ADCC activity or a high CDC activity; a hybridoma which produces the antibody; a DNA which encodes the antibody; a vector which contains the DNA; a transformant obtainable by introducing the vector; a process for producing an antibody or an antibody fragment thereof using the hybridoma or the transformant; and a therapeutic agent using the antibody or the antibody fragment thereof or a diagnostic agent using the antibody or the antibody fragment thereof.
摘要翻译： 与CD4结合的抗CD4抗体具有高亲和力并具有高效应活性，例如抗体依赖性细胞毒性（ADCC活性）或补体依赖性细胞毒性（CDC活性），涉及到疾病 到CD4表达细胞。 本发明可以提供以高亲和力结合CD4细胞外区域并且也表现出高ADCC活性或高CDC活性的单克隆抗体或其抗体片段; 产生抗体的杂交瘤; 编码抗体的DNA; 含有DNA的载体; 通过引入载体可获得的转化体; 使用杂交瘤或转化体生产抗体或其抗体片段的方法; 以及使用该抗体或其抗体片段的治疗剂或使用该抗体或其抗体片段的诊断剂。
-
公开(公告)号：US20090028877A1
公开(公告)日：2009-01-29
申请号：US10575114
申请日：2004-10-08
申请人： Shigeru Iida , Mitsuo Satoh , Miho Takabe , Masako Wakitani , Kazuhisa Uchida , Rinpei Niwa , Kenya Shitara
发明人： Shigeru Iida , Mitsuo Satoh , Miho Takabe , Masako Wakitani , Kazuhisa Uchida , Rinpei Niwa , Kenya Shitara
IPC分类号： A61K39/395 , C07K16/18 , C12N5/06 , A61P31/00 , C12P21/04
CPC分类号： C07K16/3084 , A61K2039/505 , C07K2317/52 , C07K2317/732
摘要： An anti-ganglioside GM2 antibody composition having enhanced effector function which is useful as a medicament has been desired. The present invention provides an antibody composition comprising an antibody molecule which specifically binds to ganglioside GM2 and has complex type N-glycoside-linked sugar chains in the Fc region, wherein the complex type N-glycoside-linked sugar chains have a structure in which fucose is not bound to N-acetylglucosamine in the reducing end in the sugar chains; a transformant which produces the antibody composition; a process for producing the antibody composition; and a pharmaceutical composition comprising the antibody composition.
摘要翻译： 已经需要可用作药物的具有增强的效应子功能的抗神经节苷脂GM2抗体组合物。 本发明提供一种抗体组合物，其包含特异性结合神经节苷脂GM2并且在Fc区中具有复合型N-糖苷连接的糖链的抗体分子，其中复合型N-糖苷连接的糖链具有其中岩藻糖 在糖链的还原末端不与N-乙酰氨基葡萄糖结合; 产生抗体组成的转化体; 制备抗体组合物的方法; 和包含该抗体组合物的药物组合物。
-
公开(公告)号：US20050287138A1
公开(公告)日：2005-12-29
申请号：US10959310
申请日：2004-10-07
申请人： Shigeru Iida , Mitsuo Satoh , Miho Urakubo , Masako Wakitani , Kazuhisa Uchida , Rinpei Niwa , Kenya Shitara
发明人： Shigeru Iida , Mitsuo Satoh , Miho Urakubo , Masako Wakitani , Kazuhisa Uchida , Rinpei Niwa , Kenya Shitara
IPC分类号： A61K39/395 , C07K16/28
CPC分类号： C07K16/2866 , C07K2317/41 , C07K2317/732
摘要： The present invention provides an antibody composition comprising an antibody molecule which specifically binds to human CC chemokine receptor 4 (CCR4) and has complex type N-glycoside-linked sugar chains in the Fc region, wherein the complex type N-glycoside-linked sugar chains have a structure in which fucose is not bound to N-acetylglucosamine in the reducing end in the sugar chains; a transformant which produces the antibody composition; a process for producing the antibody composition; and a pharmaceutical composition comprising the antibody composition.
摘要翻译： 本发明提供一种抗体组合物，其包含特异性结合人类CC趋化因子受体4（CCR4）的抗体分子，并且在Fc区具有复合型N-糖苷连接的糖链，其中复合型N-糖苷连接的糖链 在糖链的还原端具有岩藻糖不与N-乙酰葡糖胺结合的结构; 产生抗体组成的转化体; 制备抗体组合物的方法; 和包含该抗体组合物的药物组合物。
-
公开(公告)号：US20050031613A1
公开(公告)日：2005-02-10
申请号：US10409608
申请日：2003-04-09
IPC分类号： A61K39/395 , A61P9/00 , A61P29/00 , A61P31/04 , A61P31/12 , A61P31/14 , A61P35/00 , A61P37/02 , A61P37/04 , A61P37/08 , A61P43/00 , C07K16/00 , C07K16/18 , C07K16/44 , C12P21/08
CPC分类号： A61K39/395 , A61K2039/505 , C07K16/00 , C07K16/18 , C07K16/3084 , C07K16/44 , C07K2317/24 , C07K2317/41 , C07K2317/52 , C07K2317/732 , C07K2319/30
摘要： A medicament for treating FcγRIIIa polymorphism patients who cannot be treated by a medicament comprising as an active ingredient an antibody composition produced by a cell unresistant to a lectin which recognizes a sugar chain in which 1-position of fucose is bound to 6-position of N-acetylglucosamine in the reducing end through α-bond in a complex N-glycoside-linked sugar chain, which comprises as an active ingredient an antibody composition produced by a cell resistant to a lectin which recognizes a sugar chain in which 1-position of fucose is bound to 6-position of N-acetylglucosamine in the reducing end through α-bond in a complex N-glycoside-linked sugar chain.
摘要翻译： 一种用于治疗不能用药物治疗的FcgammaRIIIa多态性患者的药物，所述药物包含作为活性成分的抗细胞因抗细胞因子而产生的抗体组合物，所述抗体组合物识别其中1位的岩藻糖与N位的6-位结合的糖链 乙酰基葡糖胺在还原末端通过复合N-糖苷连接的糖链中的α-键，其包含作为活性成分的抗体组合物，所述抗体组合物是由能够识别糖链的细胞产生的，所述凝集素识别其中1位岩藻糖 通过复合N-糖苷连接的糖链中的α-键在还原末端与N-乙酰氨基葡萄糖的6-位结合。
-
公开(公告)号：US08883981B2
公开(公告)日：2014-11-11
申请号：US12829836
申请日：2010-07-02
申请人： Kenya Shitara , Rinpei Niwa , Akito Natsume
发明人： Kenya Shitara , Rinpei Niwa , Akito Natsume
CPC分类号： C07K16/462 , A61K2039/505 , C07K16/2887 , C07K2317/24 , C07K2317/522 , C07K2317/524 , C07K2317/526 , C07K2317/53 , C07K2317/72 , C07K2317/732 , C07K2317/734
摘要： The present invention relates to a recombinant antibody composition having higher complement-dependent cytotoxic activity than a human IgG1 antibody and a human IgG3 antibody, wherein a polypeptide comprising a CH2 domain in the Fc region of a human IgG1 antibody is replaced by a polypeptide comprising an amino acid sequence which corresponds to the same position of a human IgG3 antibody indicated by the EU index as in Kabat, et al.; a DNA encoding the antibody molecule or a heavy chain constant region of the antibody molecule contained in the recombinant antibody composition; a transformant obtainable by introducing the recombinant vector into a host cell; a process for producing the recombinant antibody composition using the transformant; and a medicament comprising the recombinant antibody composition as an active ingredient.
摘要翻译： 本发明涉及具有比人IgG1抗体和人IgG3抗体更高的补体依赖性细胞毒活性的重组抗体组合物，其中包含人IgG1抗体的Fc区中的CH2结构域的多肽被包含 氨基酸序列对应于如Kabat等人的欧盟指数所示的人IgG3抗体的相同位置; 编码重组抗体组合物中所含的抗体分子或抗体分子的重链恒定区的DNA; 通过将重组载体导入宿主细胞获得的转化体; 使用该转化体生产重组抗体组合物的方法; 以及包含重组抗体组合物作为活性成分的药物。
-
-
-
-
-
-
-
-
-
搜索结果
39 条记录 (耗时 0.023 秒)
